Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Intas cuts Razumab supplies after adv...
Home  »  Community News  »  Intas cuts Razumab s...
Intas cuts Razumab supplies after adverse eye reactions
Pharma News

MUMBAI: Indian pharmaceutical and biotechnology firm Intas Biopharmaceuticals has “curtailed the distribution” of Razumab, an injectable drug used for treating macular degeneration, barely two months after its launch following stray incidents of adverse reactions like inflammation in eyes.

Razumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25% cheaper than the innovator drug marketed by Novartis.

Two renowned eye care experts confirmed to ET that RazĀ ..

Leave a reply

You must be logged in to post a comment.